Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
396 studies found for:    "Myelofibrosis"
Show Display Options
Rank Status Study
21 Withdrawn Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
Conditions: Acute Myeloid Leukemia in Remission;   Primary Myelofibrosis;   Primary Myelofibrosis, Prefibrotic Stage;   Secondary Acute Myeloid Leukemia;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
22 Active, not recruiting LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Conditions: Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-Essential Thrombocythemia Related Myelofibrosis
Intervention: Drug: LBH589
23 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
24 Recruiting Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Conditions: Primary Myelofibrosis (PMF);   Post-polycythemia Vera (Post-PV) Myelofibrosis;   Postessential Thrombocythemia (Post-ET) Myelofibrosis
Intervention: Drug: MMB
25 Active, not recruiting
Has Results
Decitabine in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: Decitabine;   Other: Laboratory Biomarker Analysis
26 Not yet recruiting Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis;   Polycythemia Vera;   Primary Myelofibrosis;   Thrombocytopenia
Interventions: Procedure: Bone Marrow Aspiration and Biopsy;   Other: Laboratory Biomarker Analysis;   Biological: Siltuximab
27 Recruiting P1101 in Treating Patients With Early Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Other: Laboratory Biomarker Analysis;   Biological: PEG-Proline-Interferon Alfa-2b;   Other: Quality-of-Life Assessment
28 Recruiting Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Conditions: Acute Megakaryoblastic Leukemia;   Myelofibrosis;   Primary Myelofibrosis
Interventions: Drug: Alisertib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
29 Not yet recruiting Study of Ruxolitinib for Patients With Myelofibrosis (MF)
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Behavioral: Questionnaires
30 Completed
Has Results
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Condition: Myelofibrosis
Interventions: Drug: Ruxolitinib;   Drug: Placebo
31 Completed
Has Results
Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Condition: Myelofibrosis
Interventions: Drug: INC424/INCB018424;   Drug: Best Available Therapy (BAT)
32 Recruiting JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
33 Completed
Has Results
CEP-701 for PH-negative Myelofibrosis
Conditions: Leukemia;   Myelofibrosis
Intervention: Drug: CEP-701
34 Active, not recruiting Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Conditions: Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Drug: ruxolitinib phosphate;   Drug: danazol;   Other: quality-of-life assessment;   Other: questionnaire administration
35 Active, not recruiting Allogeneic Stem Cell Transplantation for Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: Thymoglobulin (ATG)
36 Recruiting A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Conditions: Primary Myelofibrosis;   Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Biological: PRM-151
37 Terminated
Has Results
Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: bevacizumab (Avastin)
38 Not yet recruiting A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Condition: Myelofibrosis
Interventions: Drug: INCB050465;   Drug: Ruxolitinib
39 Not yet recruiting Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
40 Completed Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: cyclophosphamide;   Drug: busulfan;   Drug: tacrolimus;   Drug: methotrexate;   Genetic: cytogenetic analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: pharmacogenomic studies;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years